3. Umbruch 4.4..2005 - Online Pot

The development of Sativex ® – a natural cannabis-based medicine 249
Figure 6. Relief of spasticity in MS (clinic assessments) [58]. Placebo was crossed over to Sativex ®
in weeks 7–10. Adapted from Wade et al. [58].
Figure 7. Relief of spasticity in MS (diary cards) [58]. Placebo crossed over to Sativex ® in weeks
7–10. Adapted from Wade et al. [58].
Neuropathic pain in MS
Sativex ® has been investigated for its effects on neuropathic pain from a variety
of aetiologies. A study evaluating its effects in CNP in MS was undertaken
in 2002 [55]. Following a baseline period during which their pain scores
were assessed, 66 patients with CNP were randomized to receive either
Sativex ® or placebo for 4 weeks. The primary endpoint of the study was pain
scores as measured on a patient diary card using an 11-point Numerical Rating